Oncolytics Biotech Inc T.ONC

worth a read...only a month old , recent enough

[canadafan]

https://leedejonesgable.com/wp-content/uploads/ONC_2023_03_06.pdf


Now: before anyone jumps all over this for either high or low.
Take in context. 
RBC has a rating of $6 CDN with an $18 upside on partnership and/or phase 3 registration.
The range of rating are all over the place. None or which are lower than now. 

All of which have a "buy" or "strong buy rating"
You see, boys & girls, if/when ONC gets approval, or partership. The whole game changes.
That will happen only after the Bracelt reults are released. 
The up-coming ASCO presentation is expected to be the reveal of that...with a N.R. prior.
Could a buy-out happen before? anythiing is possible. My opinion , not likely.
ONC does not want to sell-out cheap & pahrma wont pay until they see the data.
The enclosed report gives lots to chew on.

[westcoast1000]

Thanks for posting that report, CF. It is extremely thorough and well documented. It is balanced and clearly intended to let the state of the trials and the information about comparables drive their valuation. Their valuation is of course driven by their choice of the discount rate to account for uncertainties, which is 30% IIRC.  It is also driven by wating for upcoming results, which are

[inthno]

great report with a lot of caveats so hope it all goes well and am sure the process is very painstaking. As for price targets, they don't mean a lot and even the anlaysts have difficulty with their evaluations. I just wish that RBC had not downgraded onc from thier original 9 dollars to their now 6 dollars as this does not instill a lot of confidence going forward especially at this stage of